BRCA1 and cancer: Jonsson et al. found that among advanced-cancer patients with deleterious germline BRCA1/2 alleles (2.7%) or somatic loss-of-function alterations (1.8%), selective pressure for biallelic gene inactivation and PARP inhibitor sensitivity was only observed in BRCA-associated cancers (88).